Actuate Therapeutics, Inc. (ACTU) - Q2 2025 Filing Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Actuate Therapeutics is a clinical-stage biopharmaceutical company focused on developing elraglusib, a GSK-3 inhibitor, for the treatment of various cancers. The company has no approved products and has not generated any revenue from product sales since inception. As of August 13, 2025, there were 20,745,187 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(5,949,405) | $(12,266,429) | $(14,868,278) |
| Net Loss Per Share (Basic/Diluted) | $(0.30) | $(0.63) | $(9.59) |
| Cash and Cash Equivalents (End of Period) | $6,492,656 | $6,492,656 | $351,709 |
| Working Capital Deficit | $(2,512,162) | $(2,512,162) | N/A |
| Accumulated Deficit | $(144,646,278) | $(144,646,278) | $(119,962,799) |
| Net Cash Used in Operating Activities | N/A | $(8,792,501) | $(7,921,220) |
| Net Cash Provided by Financing Activities | N/A | $6,643,535 | $5,314,270 |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses for the six months ended June 30, 2025, were $12.3 million, a decrease of $0.9 million compared to $13.2 million in the same period in 2024.
- Research & Development (R&D): Decreased by $5.2 million to $6.0 million, primarily due to lower external clinical trial expenses ($5.2 million decrease) related to fewer patients on study in the Phase 2 mPDAC trial.
- General & Administrative (G&A): Increased by $4.4 million to $6.3 million, driven by higher personnel-related expenses (including $2.4 million in stock-based compensation) and increased public company costs (insurance, board fees).
- Other Income/Expense: Net other income improved significantly to $68,032 for the six months ended June 30, 2025, compared to a net expense of $(1.7) million in 2024. This improvement is largely due to the absence of non-cash losses related to the fair value changes of warrant liabilities and related party convertible notes, which were present in 2024 but resolved following the IPO in August 2024.
- Liquidity: Cash balances increased from $8.6 million at year-end 2024 to $6.5 million at June 30, 2025, despite operating cash burn, due to financing activities. However, the company reported a working capital deficit of $2.5 million.
Guidance, Outlook, and Risks
- Clinical Progress: Topline data from the Phase 2 Actuate-1801 trial in metastatic pancreatic ductal adenocarcinoma (mPDAC) announced in May 2025 met its primary endpoint, showing a statistically significant improvement in median overall survival (10.1 months vs. 7.2 months) and 1-year survival rates. A Phase 1/2 trial in pediatric malignancies was completed in July 2025, identifying Ewing sarcoma as a potential second indication.
- Capital Requirements & Going Concern: Management estimates that existing cash and cash equivalents will not satisfy operational requirements beyond October 2025. The filing explicitly states there is substantial doubt regarding the company's ability to continue as a going concern for a year from the date of issuance without raising additional capital.
- Financing Activities:
- June 2025 Private Placement: Raised net proceeds of $4.6 million by issuing 666,497 shares and warrants.
- Committed Equity Facility: Entered into an agreement with B. Riley in March 2025 to sell up to $50 million of stock. Raised $2.1 million net proceeds during Q2 2025. Subsequent to quarter-end, an additional $1.6 million was raised through August 13, 2025.
- Risks: Key risks include the inability to raise necessary capital, potential dilution from future equity sales, reliance on a single product candidate (elraglusib), and the uncertainty of regulatory approval despite positive Phase 2 data.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for the next capital raise given the "October 2025" liquidity horizon and the working capital deficit.
- Dilution Impact: Assess the potential dilution from the remaining capacity under the B. Riley Committed Equity Facility ($50 million cap) and the warrants issued in the June 2025 Private Placement.
- Clinical Data Finalization: Confirm the final analysis of the Actuate-1801 Phase 2 trial data, as the topline data is subject to audit and verification.
- Regulatory Pathway: Monitor FDA communications regarding the potential to pursue registration using Phase 2 data versus the requirement for a Phase 3 trial, which significantly impacts capital needs.
- Stock-Based Compensation: Review the trajectory of stock-based compensation expenses, which increased significantly in G&A ($2.4 million YTD 2025 vs. $0.1 million YTD 2024), as this impacts future burn rates.